neoX Biotech

neoX is a biotech company that combines artificial intelligence (AI), state-of-the-art biophysics and high-throughput experimentation to innovate highly differentiated therapeutics for unmet medical needs. neoX is focused on the discovery of macromolecular and multi-specific drug modalities, through deep insights into dynamic protein-protein interactions (PPIs). We aspire to generate Fist-in-Class and/or Best-in-Class medicines through both in-house pipeline progression and co-development with strategic partners on the global stage. Company is headquartered in Beijing, China, with research teams also located in Shanghai, China, and Boston, USA. neoX's AI/computation capabilities and deep insights into protein-protein interaction (PPI) have enabled us to build a comprehensive and highly differentiated pipeline focused on the following drug modalities: · neoBiologics: Antibody/nanobody, cytokine and protein drugs of unique activity and selectivity profile · neoDegrader: Targeted Protein Degradation (TPD) drugs guided by meta-PPI-based rational design and empowered by execution excellence in discovery of non-canonical small molecule drugs like PROTAC and Molecular Glue. Currently, we have multiple antibody-based drugs and PROTAC degraders at the candidate-selection or IND-enabling stage. We are actively seeking out-licensing opportunities for these innovative assets and looking for experienced partners to establish long-term partnerships. Website：www.neoxbio.com E-Mail：bd@neoxbio.com